GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Buyback Yield %

Astellas Pharma (Astellas Pharma) Buyback Yield % : 2.63 (As of Apr. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Astellas Pharma's current buyback yield was 2.63%.


Astellas Pharma Buyback Yield % Historical Data

The historical data trend for Astellas Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Buyback Yield % Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.11 1.74 0.29 1.50 1.78

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.87 1.14 - -

Competitive Comparison of Astellas Pharma's Buyback Yield %

For the Drug Manufacturers - General subindustry, Astellas Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Buyback Yield % falls into.



Astellas Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Astellas Pharma's Buyback Yield for the fiscal year that ended in Mar. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-453.045 + 0) / 25505.0082
=1.78%

Astellas Pharma's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.014 + 0) * 4 / 21336.581
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.


Astellas Pharma Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (Astellas Pharma) Headlines

From GuruFocus